[Analysis of Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in Our Department].
Gan To Kagaku Ryoho
; 45(10): 1504-1506, 2018 Oct.
Article
em Ja
| MEDLINE
| ID: mdl-30382059
ABSTRACT
We investigated neoadjuvant chemotherapy for patients with human epidermal growth factor receptor 2(HER2)-positive breast cancer. Twenty-eight patients with HER2-positive breast cancer received neoadjuvant chemotherapy from January 2011 to December 2017. Of the 28 patients, pathological complete response(pCR)was achieved in 14 patients. The pCR rate for the docetaxel(DTX)-containing regimen was 47.4%, whereas that for the nanoparticle albumin-bound paclitaxel(nab- PTX)-containing regimen was 71.4%. Therefore, nab-PTX-containing therapy may be more effective than a DTX-containing regimen for patients with HER2-positive breast cancer.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Terapia Neoadjuvante
Tipo de estudo:
Diagnostic_studies
Limite:
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
Ja
Ano de publicação:
2018
Tipo de documento:
Article